Dr. Taneja is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Elm and Carlton Streets
Buffalo, NY 14203Phone+1 313-745-7888- Is this information wrong?
Education & Training
University at BuffaloFellowship, Hematology and Medical Oncology, 2021 - 2024
Detroit Medical Center/Wayne State UniversityResidency, Internal Medicine, 2019 - 2021
Armed Forces Medical College, Pune, IndiaClass of 2017
Certifications & Licensure
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Gold Humanism Honor Society 2023
- Medical Educators Institute American Society of Hematology, 2023
Publications & Presentations
PubMed
- A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapies.Rahul Mishra, Danai Dima, Sumukh A Kumar, Agrima Mian, Alankrita Taneja, Rahul Karna, Paolo F Caimi, Brian T Hill, Robert Dean, Deepa Jagadeesh> ;Hematological Oncology. 2023 Dec 1
- Bone marrow Ki-67 index is of prognostic value in newly diagnosed multiple myeloma.Shebli Atrash, Myra Robinson, Alankrita Taneja, Barry Paul, Kristen Cassetta, Ami Ndiaye, Cindy Varga, Jared Block, Edward H Lipford, Elton T Smith, Chad M McCall, Vir...> ;European Journal of Haematology. 2023 Sep 1
- 2 citationsA review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022.Ravi Kumar Gupta, Ashish Gupta, Jens Hillengass, Sarah A Holstein, Vera J Suman, Alankrita Taneja, Philip L McCarthy> ;Expert Review of Anticancer Therapy. 2022 May 1
- Join now to see all
Press Mentions
World Cancer Research Day with Samuel Kareff, MD, MPH; Maria Badillo, RN; Matthew Hadfield, DO; And Alankrita Taneja, MDSeptember 29th, 2023- Multiple Myeloma Awareness Month 2024: What Patients Need to KnowMarch 26th, 2024
- Zanubrutinib plus Obinutuzumab Granted Accelerated Approval for Follicular LymphomaMarch 14th, 2024
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Other Languages
- Hindi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
